Ingrezza vs. Austedo: Market Share and Sales Projections for 2025
Discussions around the market share and sales of Ingrezza and Austedo in 2025 are influenced by their respective indications and the competitive landscape in the treatment of tardive dyskinesia.
What is Ingrezza and What Does It Treat?
Ingrezza (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia [1]. It works by reducing the release of dopamine in the brain, which can help control involuntary movements associated with tardive dyskinesia [1].
What is Austedo and What Does It Treat?
Austedo (deutetrabenazine) is another VMAT2 inhibitor indicated for the treatment of chorea associated with Huntington's disease and tardive dyskinesia [2]. Like Ingrezza, it aims to manage involuntary movements by modulating dopamine levels [2].
How Do Ingrezza and Austedo Compare in Tardive Dyskinesia Treatment?
Both Ingrezza and Austedo are VMAT2 inhibitors used to manage tardive dyskinesia, a condition characterized by involuntary, repetitive movements [1][2]. They offer alternative therapeutic options for patients experiencing these symptoms. The choice between them may depend on individual patient response, tolerability, and physician preference.
What are the Sales and Market Share Expectations for Ingrezza in 2025?
While specific 2025 market share figures are not yet available, Ingrezza has demonstrated significant growth. In 2023, Ingrezza achieved net sales of $1.6 billion [3]. Analysts have projected continued strong performance, with some anticipating Ingrezza's annual sales to reach over $2 billion by 2025, driven by its established presence in the tardive dyskinesia market and potential for expanded indications [3].
What are the Sales and Market Share Expectations for Austedo in 2025?
Austedo also holds a position in the tardive dyskinesia market. In 2023, Austedo generated $1.04 billion in net sales [4]. Future sales projections for Austedo in 2025 will depend on its continued uptake in its approved indications and competitive pressures.
When Do Ingrezza and Austedo Patents Expire?
Patent expiry dates are crucial for understanding the long-term market exclusivity of these drugs and the potential for generic competition. Information regarding the specific patent expiration timelines for Ingrezza and Austedo can be found through resources that track drug patents [5]. For instance, DrugPatentWatch.com provides comprehensive data on drug patent statuses and expiry dates [5].
What is the Competitive Landscape for Tardive Dyskinesia Treatments?
The market for tardive dyskinesia treatments includes both Ingrezza and Austedo, among other potential therapies. The landscape is competitive, with both drugs vying for market share. Future competition could also arise from new drug development or the introduction of biosimilars, depending on the drug class and patent protections.
What are the Key Differentiating Factors for These Treatments?
Key differentiating factors between Ingrezza and Austedo include their specific VMAT2 inhibition profiles, pharmacokinetic properties, dosing regimens, and side effect profiles. These elements can influence physician prescribing habits and patient outcomes.
Are There Any Clinical Data or Patient Concerns Regarding These Drugs?
Clinical trials for both Ingrezza and Austedo have established their efficacy in reducing tardive dyskinesia symptoms. Patient concerns may revolve around side effect profiles, such as somnolence or parkinsonism, and the long-term management of their condition. Ongoing research and post-market surveillance continue to inform the understanding of these drugs' safety and effectiveness.
---
Sources:
1. https://www.ingrezza.com/
2. https://www.austedo.com/
3. https://www.investors.hcentive.com/news-releases/news-release-details/horizon-therapeutics-reports-fourth-quarter-and-full-year-2023-results/
4. https://ir.teva.co.il/press-releases/press-release-details/2024/Teva-Announces-Fourth-Quarter-and-Full-Year-2023-Results/default.aspx
5. https://drugpatentwatch.com/